Compare Illumina, Inc. (ILMN) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Trip.com Group Ltd — how do they compare? Illumina, Inc. trades at $192.38 (market cap $28.96B), while Trip.com Group Ltd trades at $46.2 (market cap $29.26B). The key difference: Illumina, Inc. and Trip.com Group Ltd are close in size by market cap, and Trip.com Group Ltd pays a 0.42% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | TCOM | |
|---|---|---|
Market Cap | $28.96B | $29.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $205.10 | $78.96 |
52-Week Low | $91.00 | $39.84 |
Enterprise Value | $30.32B | $21.91B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
TCOM trades at $46.14, down 0.22% on the day, with a neutral technical signal and bearish moving averages. The company reported strong 2025 revenue of $62.41B and net income of $33.29B, with high profitability margins. Recent news includes a $770M antitrust penalty in China, impacting sentiment, while Q2 2026 earnings are expected at $0.873 per share.
Outlook remains mixed: strong fundamentals and a consensus price target of $59.29 suggest upside, but regulatory risks and recent earnings misses pose challenges. The stock offers value with a low P/E of 6.88, yet investors must weigh growth sustainability against antitrust pressures and guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
